Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5483391

N#Cc1c(N)nc(NCc2cccnc2)c(C#N)c1-c1ccccc1.O=C(O)C(F)(F)F

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.48
PDE4B Q07343 1/20 0.48
PDE4C Q08493 1/20 0.48
PDE4D Q08499 1/20 0.48
ACHE P22303 4/20 0.48
BCHE P06276 3/20 0.48
TSHR P16473 3/20 0.48
HPGD P15428 2/20 0.48
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
MAPK10 P53779 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PLAU P00749 2/20 0.47
RXFP1 Q9HBX9 1/20 0.47
ADORA1 P30542 3/20 0.44
ADORA2A P29274 1/20 0.44
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 5/20 0.44
CYP1A2 P05177 3/20 0.44
CYP3A4 P08684 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5473901 0.94 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL11924385 0.91 TSHR (0.56) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL4032360 0.87 ADORA1 (0.45) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL11924384 0.84 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL13849106 0.83 RXFP1 (0.52) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL11924394 0.82 ADORA2A (0.53) PDE4APDE4BPDE4CPDE4DTSHR
SCHEMBL11924387 0.82 ADORA1 (0.50) PDE4APDE4BPDE4CPDE4DTSHR
SCHEMBL4029100 0.81 ACHE (0.59) ACHEBCHETSHRHPGDLMNA
SCHEMBL11924411 0.81 ACHE (0.56) ACHEBCHETSHRHTTRXFP1
SCHEMBL11924423 0.80 PDE4A (0.57) PDE4APDE4BPDE4CPDE4DTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130040992-A1 Substituted 2, 6-Diamino-3, 5-Dicyano-4-Aryl-Pyridines And Their Use As Adenosine-Receptor-Selective Ligands BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-14 US disclosed
US-8242281-B2 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-08-14 US disclosed
US-20070213372-A1 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands BAYER AKTIENGESELLSCHAFT (DE) 2007-09-13 US disclosed
US-20040162427-A1 Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands BAYER AKTIENGESELLSCHAFT (DE) 2004-08-19 US disclosed
EP-1373265-A1 SUBSTITUTED 2,6-DIAMINO-3,5-DICYANO-4-ARYL-PYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS Bayer HealthCare AG (DE) 2004-01-02 EP disclosed
WO-2002070520-A1 SUBSTITUTED 2,6-DIAMINO-3,5-DICYANO-4-ARYL-PYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS BAYER AKTIENGESELLSCHAFT (DE) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162427-A1 Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands ADORA2A, ADORA3, ADORA1 PDE4A 178/4885PDE4B 175/4885PDE4C 304/4885
US-20130040992-A1 Substituted 2, 6-Diamino-3, 5-Dicyano-4-Aryl-Pyridines And Their Use As Adenosine-Receptor-Selective Ligands ADORA3, ADORA1, ADORA2A PDE4A 115/4885PDE4B 118/4885PDE4C 182/4885
US-20070213372-A1 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands ADORA3, ADORA1, ADORA2A PDE4A 128/4885PDE4B 140/4885PDE4C 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.